The first group of volunteers has been dosed and further groups will participate in the study over the coming months. This study will investigate the pharmacokinetics, safety and tolerability of Medherant’s patch product and is recruiting post-menopausal women using hormone replacement therapy. Full results from this study are expected in the first quarter of 2024.
““We are thrilled at Medherant to reach this important milestone in the development of our testosterone patch,” says Karolina Afors MBBS MRCOG, Medherant’s Medical Director. “This Phase 1 trial represents the first step in a promising journey towards providing a more effective and patient-centric approach to menopause hormone therapy.”
Medherant’s lead development product is a testosterone patch for post-menopausal women utilising Medherant’s novel transdermal TEPI Patch proprietary technology. Despite the recommendation contained in the NICE Menopause Guidelines and Global Consensus Position Statement on the Use of Testosterone Therapy for Women there is no approved testosterone product for women.
The company was founded by University of Warwick’s Professor of Polymer Chemistry, Professor David Haddleton and is developing the novel transdermal TEPI Patch technology which can create patches that have more favourable wear characteristics for patients, with good adhesion and are non-irritant to patients whilst not leaving adhesive residue on patients’ skin.
In addition to developing its own products, Medherant collaborates with pharmaceutical companies in developing transdermal patch products for already approved drugs.
TEPI Patch is a registered trademark of Medherant Limited.